![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DCAF15 |
Gene summary for DCAF15 |
![]() |
Gene information | Species | Human | Gene symbol | DCAF15 | Gene ID | 90379 |
Gene name | DDB1 and CUL4 associated factor 15 | |
Gene Alias | C19orf72 | |
Cytomap | 19p13.12 | |
Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | Q66K64 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
90379 | DCAF15 | male-WTA | Human | Thyroid | PTC | 1.19e-04 | 1.43e-01 | 0.1037 |
90379 | DCAF15 | PTC05 | Human | Thyroid | PTC | 4.70e-03 | 1.43e-01 | 0.2065 |
90379 | DCAF15 | PTC06 | Human | Thyroid | PTC | 3.41e-10 | 2.35e-01 | 0.2057 |
90379 | DCAF15 | PTC07 | Human | Thyroid | PTC | 1.08e-10 | 1.86e-01 | 0.2044 |
90379 | DCAF15 | ATC12 | Human | Thyroid | ATC | 3.00e-03 | 1.12e-01 | 0.34 |
90379 | DCAF15 | ATC13 | Human | Thyroid | ATC | 1.43e-07 | 2.29e-01 | 0.34 |
90379 | DCAF15 | ATC2 | Human | Thyroid | ATC | 9.94e-09 | 7.92e-01 | 0.34 |
90379 | DCAF15 | ATC4 | Human | Thyroid | ATC | 7.10e-07 | 1.51e-01 | 0.34 |
90379 | DCAF15 | ATC5 | Human | Thyroid | ATC | 5.68e-11 | 2.69e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000020920 | Thyroid | PTC | protein polyubiquitination | 128/5968 | 236/18723 | 7.81e-13 | 3.65e-11 | 128 |
GO:0000209110 | Thyroid | ATC | protein polyubiquitination | 134/6293 | 236/18723 | 1.86e-13 | 9.20e-12 | 134 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DCAF15 | insertion | Frame_Shift_Ins | novel | c.1024_1025insTCAAGACCAGTGTGGCCAACACGGTGAAA | p.Ala342ValfsTer31 | p.A342Vfs*31 | Q66K64 | protein_coding | TCGA-AN-A0FV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
DCAF15 | SNV | Missense_Mutation | novel | c.199N>T | p.Asn67Tyr | p.N67Y | Q66K64 | protein_coding | tolerated(0.19) | benign(0.444) | TCGA-C5-A8XI-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
DCAF15 | SNV | Missense_Mutation | novel | c.211N>A | p.Glu71Lys | p.E71K | Q66K64 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
DCAF15 | SNV | Missense_Mutation | c.973N>A | p.Ala325Thr | p.A325T | Q66K64 | protein_coding | tolerated(0.12) | possibly_damaging(0.725) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
DCAF15 | SNV | Missense_Mutation | c.100N>A | p.Glu34Lys | p.E34K | Q66K64 | protein_coding | tolerated_low_confidence(0.27) | benign(0.025) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
DCAF15 | SNV | Missense_Mutation | c.1196N>A | p.Gly399Glu | p.G399E | Q66K64 | protein_coding | tolerated(0.54) | benign(0.155) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
DCAF15 | SNV | Missense_Mutation | c.1640N>A | p.Val547Asp | p.V547D | Q66K64 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
DCAF15 | SNV | Missense_Mutation | rs747289982 | c.1376G>A | p.Arg459His | p.R459H | Q66K64 | protein_coding | tolerated(0.09) | probably_damaging(0.998) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DCAF15 | SNV | Missense_Mutation | rs747289982 | c.1376G>A | p.Arg459His | p.R459H | Q66K64 | protein_coding | tolerated(0.09) | probably_damaging(0.998) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DCAF15 | SNV | Missense_Mutation | novel | c.198G>T | p.Lys66Asn | p.K66N | Q66K64 | protein_coding | deleterious(0) | possibly_damaging(0.663) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |